“Immunotherapy has grabbed our attention [in oncology], and it is not the end of the story,” declared Anthony J. Olszanski, RPh, MD, Associate Professor, Director of the Phase I Developmental Therapeutics Program, and Director of the Medical Oncology Melanoma Program at Fox Chase Cancer Center. “The future will not be just about immunotherapy, but rather the combination of both immunotherapies and cytotoxic therapies,” predicted Dr. Olszanski, who currently serves on the NCCN Guidelines Panel for Melanoma.
SchreiberRD. Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting. Cancer Immun2005;5(Suppl 1):1.
GalonJCostesASanchez-CaboF. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science2006;313:1960–1964.
AtkinsMBLotzeMTDutcherJP. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol1999;17:2105–2116.
AnsellSMLesokhinAMBorrelloI. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med2015;372:311–319.
TopalianSLSznolMBrahmerJR. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: survival and long-term safety in a phase I trial [abstract]. J Clin Oncol2013;31(Suppl):Abstract 3002.
PostowMAChesneyJPavlickAC. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med2015[e-pub ahead of print].
SegalNHAntoniaSJBrahmerJR. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody [abstract]. J Clin Oncol2014;32(Suppl):Abstract 3002.